Menu IR Home IR Home News Releases Events and Presentations Stock Information Stock Quote Interactive Stock Chart Key Ratios Analyst Coverage FAQs Financials and SEC Filings Annual Reports and Proxies Quarterly Financial Reports SEC Filings Corporate Governance Documents and Charters Management Board of Directors Committee Composition Contact the Board Contact Us News Releases Investor Alerts Year All Years 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Sep 18, 2019 Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist Sep 11, 2019 Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019 Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis Sep 5, 2019 Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range - Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose - Sep 3, 2019 Immunic, Inc. to Participate in Scientific and Investor Conferences in September Aug 12, 2019 Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis - Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic - Show 5102550100 per page«123456789»
